169 related articles for article (PubMed ID: 36720643)
1. The Small Molecule Antagonist KCI807 Disrupts Association of the Amino-Terminal Domain of the Androgen Receptor with ELK1 by Modulating the Adjacent DNA Binding Domain.
Soave C; Ducker C; Islam N; Kim S; Yurgelevic S; Nicely NI; Pardy L; Huang Y; Shaw PE; Auner G; Dickson A; Ratnam M
Mol Pharmacol; 2023 Apr; 103(4):211-220. PubMed ID: 36720643
[TBL] [Abstract][Full Text] [Related]
2. Strategy for Tumor-Selective Disruption of Androgen Receptor Function in the Spectrum of Prostate Cancer.
Rosati R; Polin L; Ducker C; Li J; Bao X; Selvakumar D; Kim S; Xhabija B; Larsen M; McFall T; Huang Y; Kidder BL; Fribley A; Saxton J; Kakuta H; Shaw P; Ratnam M
Clin Cancer Res; 2018 Dec; 24(24):6509-6522. PubMed ID: 30185422
[TBL] [Abstract][Full Text] [Related]
3. Identification of ELK1 interacting peptide segments in the androgen receptor.
Soave C; Ducker C; Kim S; Strahl T; Rosati R; Huang Y; Shaw PE; Ratnam M
Biochem J; 2022 Jul; 479(14):1519-1531. PubMed ID: 35781489
[TBL] [Abstract][Full Text] [Related]
4. The Amino-terminal Domain of the Androgen Receptor Co-opts Extracellular Signal-regulated Kinase (ERK) Docking Sites in ELK1 Protein to Induce Sustained Gene Activation That Supports Prostate Cancer Cell Growth.
Rosati R; Patki M; Chari V; Dakshnamurthy S; McFall T; Saxton J; Kidder BL; Shaw PE; Ratnam M
J Biol Chem; 2016 Dec; 291(50):25983-25998. PubMed ID: 27793987
[TBL] [Abstract][Full Text] [Related]
5. The ETS domain transcription factor ELK1 directs a critical component of growth signaling by the androgen receptor in prostate cancer cells.
Patki M; Chari V; Sivakumaran S; Gonit M; Trumbly R; Ratnam M
J Biol Chem; 2013 Apr; 288(16):11047-65. PubMed ID: 23426362
[TBL] [Abstract][Full Text] [Related]
6. Silodosin inhibits prostate cancer cell growth via ELK1 inactivation and enhances the cytotoxic activity of gemcitabine.
Kawahara T; Aljarah AK; Shareef HK; Inoue S; Ide H; Patterson JD; Kashiwagi E; Han B; Li Y; Zheng Y; Miyamoto H
Prostate; 2016 Jun; 76(8):744-56. PubMed ID: 26864615
[TBL] [Abstract][Full Text] [Related]
7. Androgen receptor knockdown enhances prostate cancer chemosensitivity by down-regulating FEN1 through the ERK/ELK1 signalling pathway.
Xie W; Li S; Guo H; Zhang J; Tu M; Wang R; Lin B; Wu Y; Wang X
Cancer Med; 2023 Jul; 12(14):15317-15336. PubMed ID: 37326412
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of androgen receptor transactivation function by adenovirus type 12 E1A undermines prostate cancer cell survival.
Li D; Tian G; Wang J; Zhao LY; Co O; Underill ZC; Mymryk JS; Claessens F; Dehm SM; Daaka Y; Liao D
Prostate; 2018 Nov; 78(15):1140-1156. PubMed ID: 30009471
[TBL] [Abstract][Full Text] [Related]
9. Androgen receptor and its splice variant, AR-V7, differentially regulate FOXA1 sensitive genes in LNCaP prostate cancer cells.
Krause WC; Shafi AA; Nakka M; Weigel NL
Int J Biochem Cell Biol; 2014 Sep; 54():49-59. PubMed ID: 25008967
[TBL] [Abstract][Full Text] [Related]
10. The ternary complex factor protein ELK1 is an independent prognosticator of disease recurrence in prostate cancer.
Pardy L; Rosati R; Soave C; Huang Y; Kim S; Ratnam M
Prostate; 2020 Feb; 80(2):198-208. PubMed ID: 31794091
[TBL] [Abstract][Full Text] [Related]
11. ELK1 is up-regulated by androgen in bladder cancer cells and promotes tumor progression.
Kawahara T; Shareef HK; Aljarah AK; Ide H; Li Y; Kashiwagi E; Netto GJ; Zheng Y; Miyamoto H
Oncotarget; 2015 Oct; 6(30):29860-76. PubMed ID: 26342199
[TBL] [Abstract][Full Text] [Related]
12. Development of Novel Inhibitors Targeting the D-Box of the DNA Binding Domain of Androgen Receptor.
Radaeva M; Ban F; Zhang F; LeBlanc E; Lallous N; Rennie PS; Gleave ME; Cherkasov A
Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33801338
[TBL] [Abstract][Full Text] [Related]
13. Combination therapy with androgen receptor N-terminal domain antagonist EPI-7170 and enzalutamide yields synergistic activity in AR-V7-positive prostate cancer.
Hirayama Y; Tam T; Jian K; Andersen RJ; Sadar MD
Mol Oncol; 2020 Oct; 14(10):2455-2470. PubMed ID: 32734688
[TBL] [Abstract][Full Text] [Related]
14. MED19 alters AR occupancy and gene expression in prostate cancer cells, driving MAOA expression and growth under low androgen.
Weber H; Ruoff R; Garabedian MJ
PLoS Genet; 2021 Jan; 17(1):e1008540. PubMed ID: 33513133
[TBL] [Abstract][Full Text] [Related]
15. Selectively targeting the DNA-binding domain of the androgen receptor as a prospective therapy for prostate cancer.
Dalal K; Roshan-Moniri M; Sharma A; Li H; Ban F; Hessein M; Hsing M; Singh K; LeBlanc E; Dehm S; Tomlinson Guns ES; Cherkasov A; Rennie PS
J Biol Chem; 2014 Sep; 289(38):26417-26429. PubMed ID: 25086042
[TBL] [Abstract][Full Text] [Related]
16. Selectively targeting the dimerization interface of human androgen receptor with small-molecules to treat castration-resistant prostate cancer.
Dalal K; Ban F; Li H; Morin H; Roshan-Moniri M; Tam KJ; Shepherd A; Sharma A; Peacock J; Carlson ML; LeBlanc E; Perez C; Duong F; Ong CJ; Rennie PS; Cherkasov A
Cancer Lett; 2018 Nov; 437():35-43. PubMed ID: 30165195
[TBL] [Abstract][Full Text] [Related]
17. Regression of castration-resistant prostate cancer by a novel compound QW07 targeting androgen receptor N-terminal domain.
Peng S; Wang J; Chen H; Hu P; He XL; He Y; Wang M; Tang W; He Q; Wang YY; Xie J; Guo D; Ren S; Liu M; Qiu WW; Yi Z
Cell Biol Toxicol; 2020 Oct; 36(5):399-416. PubMed ID: 32002708
[TBL] [Abstract][Full Text] [Related]
18. Development of a Benzothiazole Scaffold-Based Androgen Receptor N-Terminal Inhibitor for Treating Androgen-Responsive Prostate Cancer.
Kuznik NC; Solozobova V; Jung N; Gräßle S; Lei Q; Lewandowski EM; Munuganti R; Zoubeidi A; Chen Y; Bräse S; Cato ACB
ACS Chem Biol; 2021 Nov; 16(11):2103-2108. PubMed ID: 34506104
[TBL] [Abstract][Full Text] [Related]
19. Characterization of nuclear import of the domain-specific androgen receptor in association with the importin alpha/beta and Ran-guanosine 5'-triphosphate systems.
Kaku N; Matsuda K; Tsujimura A; Kawata M
Endocrinology; 2008 Aug; 149(8):3960-9. PubMed ID: 18420738
[TBL] [Abstract][Full Text] [Related]
20. Discovery of novel antagonists targeting the DNA binding domain of androgen receptor by integrated docking-based virtual screening and bioassays.
Pang JP; Shen C; Zhou WF; Wang YX; Shan LH; Chai X; Shao Y; Hu XP; Zhu F; Zhu DY; Xiao L; Xu L; Xu XH; Li D; Hou TJ
Acta Pharmacol Sin; 2022 Jan; 43(1):229-239. PubMed ID: 33767381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
